A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma CARTITUDE-4

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506588-32-00

Acronym

68284528MMY3002

Enrollment

233

Registered

2024-03-21

Start date

2020-06-12

Completion date

Unknown

Last updated

2025-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed and Lenalidomide-Refractory Multiple Myeloma

Brief summary

Progression-free survival (PFS)

Interventions

DRUGImnovid 3 mg hard capsules

DRUGCARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion

DRUGPomalidomide

DRUGFLUDARABINE

DRUGDARZALEX 1800 mg solution for injection

DRUGImnovid 2 mg hard capsules

DRUGCYCLOPHOSPHAMIDE

DRUGImnovid 4 mg hard capsules

DRUGBORTEZOMIB

DRUGDexamethasone Tablets BP 2.0mg

DRUGImnovid 1 mg hard capsules

DRUGFortecortin® 2 mg Tabletten

DRUGDexamethason 4 mg JENAPHARM®

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS)	—

Countries

Belgium, Denmark, France, Germany, Greece, Italy, Netherlands, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026